CTLA-4 therapy and dementia: A review of immunomodulation in neurodegenerative disease

The immuno-oncological application of CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) therapy currently draws scientific interest as a potential treatment tool for combating dementia and neurodegenerative disorders. Research shows neurodegeneration's link to immune system involvement since immunomodulatory treatments might affect disease progression. The immune checkpoint inhibitor CTLA-4 controls T-cell activity while reducing inflammatory processes, which are crucial factors in triggering Alzheimer’s disease, dementia, and related conditions. Research shows that inhibiting CTLA-4 helps protect the brain by controlling microglial activity, yet ongoing studies are being conducted to determine the potential risks of autoimmune responses in these central nervous structures. The review examines how CTLA-4 therapy affects neurodegeneration together with its clinical value and its potential side effects. Procedures that modify CTLA-4 functioning remain under clinical investigation for dementia management, while scientific trials are needed to verify their safety alongside their effectiveness.